New York, NY -- (SBWIRE) -- 12/16/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Annaly Capital Management, Inc (NYSE:NLY), Advanced Micro Devices, Inc (NYSE:AMD), Ariad Pharmaceuticals, Inc (NASDAQ:ARIA), XOMA Corp (NASDAQ:XOMA)
Annaly Capital Management, Inc (NYSE:NLY) the stock opened the session at $10.03 but then moved to $9.94. At that price, the stock showed a negative performance of -0.30%. Annaly Capital Management, Inc. (Annaly) owns, manage, and finance a portfolio of real estate related investments, including mortgage pass-through certificates, collateralized mortgage obligations (CMOs), Agency callable debentures, and other securities representing interests in or obligations backed by pools of mortgage loans. The Company's wholly owned subsidiaries offer diversified real estate, asset management and other financial services. The Company's subsidiary, RCap Securities, Inc. (RCap), operates as a broker-dealer.
Will NLY Get Buyers Even After The Recent Rally? Find Out Here
Advanced Micro Devices, Inc (NYSE:AMD) opened the session at $3.70 and closed the session at $3.69. Traded with volume of 9.07 shares in the prior session and the average volume of the stock remained 16.14 million shares. Advanced Micro Devices, Inc. (AMD) is a global semiconductor company with facilities around the world. The Company offers x86 microprocessors, as standalone devices or as incorporated as an accelerated processing unit (APU), for the commercial and consumer markets, embedded microprocessors for commercial, commercial client and consumer markets and chipsets for desktop and mobile devices, including mobile personal computers, or PCs,
Is AMD a Solid Investment at These Levels? Read This Report For Details
Ariad Pharmaceuticals, Inc (NASDAQ:ARIA) opened the session at $4.10 and closed the session at $3.98. The stock showed a negative performance of -1.73% in previous trading session. The beta of the stock remained 0.81. ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD’s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy.
Why Should Investors Buy ARIA After the Recent Fall? Just Go Here and Find Out
XOMA Corp (NASDAQ:XOMA) the stock decreased -6.89% and finished the session at $5.27. The beta of the stock remained 2.39. XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company’s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo,
Will XOMA Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)